Outcomes | LDDs v placebo | LDDs v β blockers | LDDs v ACE inhibitors | LDDs v CCBs | LDDs v ARBs | LDDs v α blockers |
---|---|---|---|---|---|---|
*ACE = angiotensin converting enzyme; CCBs = calcium channel blockers; ARBs = angiotensin receptor blockers; CHD = coronary heart disease; CHF = congestive heart failure; CVD = cardiovascular disease. CI defined in glossary. All significant differences favour LDDs. RRs <1.0 favour LDDs; RRs >1.0 favour the alternative treatment. | ||||||
†Statistically significant. | ||||||
CHD | 0.79 (0.69 to 0.92)† | 0.87 (0.74 to 1.03) | 1.00 (0.88 to 1.14) | 0.89 (0.76 to 1.01) | 0.83 (0.59 to 1.16) | 0.99 (0.75 to 1.31) |
CHF | 0.51 (0.42 to 0.62)† | 0.83 (0.68 to 1.01) | 0.88 (0.80 to 0.96)† | 0.74 (0.67 to 0.81)† | 0.88 (0.66 to 1.16) | 0.51 (0.43 to 0.60)† |
Stroke | 0.71 (0.63 to 0.81)† | 0.90 (0.76 to 1.06) | 0.86 (0.77 to 0.97)† | 1.02 (0.91 to 1.14) | 1.20 (0.93 to 1.55) | 0.85 (0.66 to 1.10) |
CVD events | 0.76 (0.69 to 0.83)† | 0.89 (0.80 to 0.98)† | 0.94 (0.89 to 1.00) | 0.94 (0.89 to 1.00) | 1.00 (0.85 to 1.18) | 0.84 (0.75 to 0.93)† |
CVD mortality | 0.81 (0.73 to 0.92)† | 0.93 (0.81 to 1.07) | 0.93 (0.85 to 1.02) | 0.95 (0.87 to 1.04) | 1.07 (0.85 to 1.36) | 1.00 (0.75 to 1.34) |
Total mortality | 0.90 (0.84 to 0.96)† | 0.99 (0.91 to 1.07) | 1.00 (0.95 to 1.05) | 1.03 (0.98 to 1.08) | 1.09 (0.96 to 1.22) | 0.98 (0.88 to 1.10) |